Menu Content/Inhalt
Home
Debio 025

Debio 025 (alisporivir) is the first in a new class of drugs called cyclophilin inhibitors, which could become part of the future standard of care for hepatitis C. Debio 025 has a lower potential for resistance selection. Debiopharm obtained positive efficacy results of a phase IIa study with Debio 025.
Debio 025 has been shown to have a potent inhibitory effect on hepatitis C virus (HCV) replication when used alone or in combination with Interferon (IFN).
The product is currently in phase IIb for the treatment of hepatitis C.
Debio 025 has been licenced to Novartis for the entire world except Japan.

Press Releases

09-Feb-2010 30-Apr-2009 28-Apr-2009 23-Jan-2009 28-Apr-2008 -> All Press Releases

Publications

11-Jun-2009 08-May-2009 02-Feb-2009 22-Dec-2008 16-Sep-2008 -> All Publications